LATEST PRESS RELEASE

Amorfix closes private placement offering

April 16, 2014

View

Amorfix closes private placement offering

April 2, 2014

View

Former Amorfix board member Walter von Wartburg to act as board advisor

March 20, 2014

View

View All Amorfix Press Releases

TSX:AMF listed

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including ALS, cancer, and Alzheimer's Disease.

Amorfix is a pioneer in the ability to identify unique regions that are buried in normal proteins, and exposed to antibodies when proteins are aberrantly folded. These unique regions are designated Disease Specific Epitopes™ (DSE), which can be exploited by Amorfix to develop highly specific diagnostic tools, as well as targets for therapeutics of protein misfolding diseases.

amorfix life sciences